



DexTech
Know-how in Translational Research

DexTech Medical AB
Year-end report July 1, 2023 - June 30, 2024

By "Company" or "DexTech" is meant DexTech Medical AB with organization number 556664-6203.

Summary of year-end report

Fourth quarter (2024-04-01 – 2024-06-30)

- Net sales amounted to SEK 0.0 million (0.0)
- Operating profit amounted to SEK -1.6 million (-1.3)
- Earnings per share* SEK -0.07 (-0.06)

Full year (2023-07-01 – 2024-06-30)

- Net sales amounted to SEK 0.0 million (0.0)
- Operating profit amounted to SEK -5.5 million (-4.9)
- Earnings per share* SEK -0.25 (-0.25)
- Cash and cash equivalents at the end of the financial year amounted to SEK 19.0 (25.2) million

* Before and after dilution. Earnings per share: Profit for the period divided by the average number of shares 18,485,857. For the comparison period, the average number of shares was 18,485,857. Amounts in brackets refer to the corresponding period last year.

Comments from the CEO

On August 12, DexTech Medical announced new positive results from the myeloma study. The Phase 1 study examines the efficacy of OsteoDex in patients with progressive treatment-resistant multiple myeloma (MM). Progressive disease means that the disease progresses and does not respond to existing treatment. The first dose group (3mg/kg) is now ready and the DMC (Data Monitoring Committee) has approved the start of dose group 2 (6mg/kg). DMC assesses all analysis results to decide on the next higher dose. No side effects related to OsteoDex have been noted. All patients show a decrease in skeletal biomarkers. **Three out of four patients have stable disease after completion of treatment (stable = no progression of the disease).** Patients with stable disease will be followed up until new progress according to the approved amendment, which provides information on how long the treatment effect lasts.

The principal investigator (PI) is Dr Katarina Uttervall, MD, PhD, Department of Hematology/HERM, Karolinska University Hospital, Huddinge. Biomarkers are analysed at the Central Laboratory, Karolinska University Hospital, NKS, Solna. Patients with relapsed/treatment-resistant disease who have received 1–5 prior lines of therapy are included. The primary objective is to confirm safety and tolerability and as a secondary objective to determine any treatment response. Documentation of quality of life will also be done (QoL scores).

The first patient was treated in December at Karolinska University Hospital in Huddinge. The first test results from patient 1 were received on 23 January and show a very strong effect on the marker of osteoclasts activity (CTX). The patient has now completed treatment according to the study protocol and now has stable disease. Stable disease means that the disease does not progress (slowed down). The results are important and indicate that Osteodex can slow relapsed/treatment-resistant disease.

DexTech Medical

The fact that three out of four patients respond to treatment with the lowest dose exceeds all expectations. We look forward with excitement to treatment with higher doses.

Anders R Holmberg

Significant events during the financial year (July 2023 - June 2024)

DexTech announced on October 13, 2023 that the Company has filed a new patent application regarding GMP production (Good Manufacturing Practice) of the company's lead candidate OsteoDex to the European Patent Office (EPO.Org). The application describes a GMP synthesis method on a larger scale that results in a product of pharmaceutical grade as well as OsteoDex use for the treatment of cancer that develops in the skeleton.

On December 13, 2023, DexTech announced that the first patient was treated during week 50 at Karolinska University Hospital in Huddinge in the myeloma study. The Phase 1 study examines the efficacy of OsteoDex in patients with progressive treatment-resistant multiple myeloma (MM). The study includes a maximum of 20 patients and is initially being conducted at two hospitals in Sweden: Karolinska University Hospital Huddinge and Uddevalla Hospital. The treatment lasts for a total of 14 weeks with 2 doses per month. Three dose levels are being studied. The Principal Investigator (PI) is Dr Katarina Uttervall, MD, PhD, Department of Hematology/HERM, Karolinska University Hospital Huddinge. Analysis of biomarkers takes place at the Central Laboratory, Karolinska University Hospital Solna, NKS. Inclusion criteria include adult MM patients with relapsed (progressive) treatment-resistant disease, who received 1–5 prior lines of therapy. The primary objective is to confirm safety and tolerability and with a secondary objective to determine treatment response. Biochemical markers are being analyzed on an ongoing basis and the first analysis results are expected in Q1 -24.

DexTech announced on January 23 that the first test results from patient 1 had been received and showed a very strong effect on the marker of osteoclasts activity (CTX, osteoclasts break down bone and CTX mirrors osteoclast activity that is elevated in multiple myeloma). The value from baseline (baseline at screening) for CTX decreases after 3 doses of OsteoDex by approximately 80%. Other values are fairly constant (cf. baseline). The patient now has stable disease after completing treatment.

On April 15, DexTech Medical announced new positive results from the myeloma study. The Phase 1 study examines the *effect of OsteoDex* on patients with *progressive* multiple myeloma (MM). Progressive disease means that the disease progresses and does not respond to existing treatment. A patient who has shown a sharp reduction in skeletal biomarkers and who has now completed his treatment is found to have *stable disease* with continued low values of markers that reflect skeletal activity. Stable disease means that the disease does not develop/progress, which is very positive. The company now intends to follow patients with stable disease up to 2 years after completion of OsteoDex treatment. A so-called amendment has been submitted to the relevant authorities. The follow-up provides the Company with valuable information on how long the effect of OsteoDex lasts. Recruitment of patients is relatively slow (competing studies, inclusion requirements), which means that the completion of the study is slightly postponed to Q2, 2025. This means that study costs are also postponed and which means that the Company is financed throughout 2025.

Events after the end of the financial year

On August 12, DexTech Medical announced new positive results from the myeloma study. The Phase 1 study examines the effect of OsteoDex on patients with progressive multiple myeloma (MM). Progressive disease means that the disease progresses and does not respond to existing treatment. The first dose group (3mg/kg) is now ready and the DMC (Data Monitoring Committee) has approved the start of dose group 2 (6mg/kg). DMC assesses all analysis results to decide on the next higher dose. No side effects related to OsteoDex have been noted. All patients show a decrease in skeletal biomarkers. Three out of four patients have stable disease after completion of treatment (stable = no progression of the disease). Patients with stable disease will be followed up until new progress according to the approved amendment, which provides information on how long the treatment effect lasts.

Financial overview

	Quarter 4		Full year	
	2024-04-01	2023-04-01	2023-07-01	2022-07-01
	2024-06-30	2023-06-30	2024-06-30	2023-06-30
Net sales, TSEK	–	–	–	–
Profit after net financial items, SEK thousand	-1 292	-1 113	-4 706	-4 590
Earnings per share SEK*	-0,07	-0,06	-0,25	-0,25
Cash flow from operating activities, TSEK			-808	-1 552
Cash flow from investing activities, TSEK			-5 385	-8 711
Cash flow from financing activities, TSEK			–	26
Cash flow for the year, TSEK			-6 193	-10 237
* before and after dilution				
	2024-06-30	2023-06-30		
Cash and cash equivalents SEK thousand	19 043	25 236		
Balance sheet total TSEK	30 588	35 031		
Equity ratio %	97	98		

Results, fourth quarter, April-June 2024

Sales and earnings

Net sales amounted to SEK 0.0 (0.0) million in the fourth quarter. Operating profit amounted to SEK -1.6 (-1.3) million. During the quarter, costs of SEK 1.6 (1.7) million were capitalized for drug development and patents. Operating expenses amounted to SEK 3.2 (2.9) million and consist of personnel costs SEK 0.3 (0.3) million, other external costs SEK 1.7 (1.6) million and depreciation and amortization SEK 1.2 (1.0) million. Other external costs include costs for regulatory control of SEK 0.9 million and hospital costs of SEK 0.3 million for the MM study. Profit after tax amounted to SEK -1.3 (-1.1) million.

Results, full year, July 2023 - June 2024

Sales and earnings

Net sales amounted to SEK 0.0 (0.0) million during the financial year. Operating profit amounted to SEK -5.5 (-4.9) million. During the financial year, costs of SEK 5.4 (8.7) million were capitalized for drug development and patents. Operating expenses amounted to SEK 10.9 M (13.7) and consist of personnel costs SEK 1.2 M (1.1), other external costs SEK 6.1 M (9.5) and depreciation and amortization of SEK 3.7 M (3.1). Other external costs include costs for patents SEK 0.5 million, regulatory control SEK 3.9 million and hospital costs SEK 0.5 million for the MM study. Profit after tax amounted to SEK -4.7 (-4.6) million.

Liquidity and financing

Cash and cash equivalents at the end of the financial year amounted to SEK 19.0 (25.2) million.

Cash flow for the period amounted to SEK -6.2 (-10.2) million.

Financing is done with equity. Equity at the end of the financial year amounted to SEK 29.6 (34.3) million, corresponding to SEK 1.60 (1.86) per share. The equity/assets ratio was 97 (98) percent.

Working capital

In December 2021, DexTech carried out a rights issue that raised SEK 46.3 million before issue costs. Net proceeds of SEK 37.1 million to DexTech after issue costs of SEK 9.2 million. The Rights Issue 2021 ensured continued operations until the end of 2025. The goal is for license revenues to finance operations thereafter.

DexTech Medical

Activities

DexTech Medical, org.nr 556664-6203 based in Stockholm, Sweden, develops drug candidates with applications in urological oncology, primarily prostate cancer. Operations commenced on August 9, 2004 and the Company was listed on the Spotlight Stock Market on June 19, 2014.

The company has a strong clinical foundation with valuable specialist expertise, from research laboratory and manufacturing to clinical oncology. Research and development is conducted cost-effectively through collaboration in a global network.

Based on a proprietary patented technology platform, GuaDex, the Company has developed four different drug candidates, OsteoDex, SomaDex, CatDex & GuaDex and a PSMA-binding conjugate, with patents/patent applications in several key markets.

- The company's lead candidate, *OsteoDex*, for the treatment of bone metastases in castration-resistant prostate cancer, CRPC, has after extensive preclinical studies shown strong tumoricidal effect and potent inhibition of bone degradation. After a successful phase I/IIa study where the results show high tolerability with only mild side effects and a clear effect in the highest dose group, a clinical phase IIb study (efficacy study) was initiated in the autumn of 2014. The full Phase IIb clinical study report (CSR) from the Phase IIb study for OsteoDex was completed in December 2018 and in June DexTech's Phase IIb study was completed with the receipt of 2-year follow-up results from the last patients. The study, which was conducted in Sweden, Finland, Estonia and Latvia, included 55 well-defined patients with castration-resistant prostate cancer with bone metastases (mCRPC).
- *SomaDex* for the treatment of acromegaly, neuroendocrine tumors and palliative care in advanced prostate cancer. SomaDex is a drug candidate based on an endogenous hormone, somatostatin, for the treatment of acromegaly, neuroendocrine tumors and palliative treatment in advanced prostate cancer. SomaDex has undergone a Phase I clinical study (in Sweden/Finland) and a Phase II pilot study in Mexico. The studies showed that SomaDex has few and mild side effects (phase I) and has a palliative effect in advanced prostate cancer (pilot study).
- *CatDex & GuaDex*: *GuaDex* is the so-called technology platform and is a charge-modified dextran molecule with tumor-toxic properties (kills tumor cells) and is a development of CatDex.
- *PSMA-binding conjugate*, for target-specific treatment of mCRPC that overexpresses PSMA (prostate specific membrane antigen). The compound is based on the platform, GuaDex.

DexTech's goal is to out-license each drug candidate no later than after completion of the phase II study.

The technology platform, which can be likened to a "Lego box" with multiple opportunities to build new molecules, can also be out-licensed.

The following parameters have been important for DexTech's positive development to date:

- modified generics with well-documented mechanisms of action that are patented, entailing a lower risk in clinical development;
- early proof-of-concept data;
- strong clinical foundation with daily contact in clinical oncology;
- networked, academically and commercially;
- minimized fixed costs;
- Capital has been dedicated to drug development and patents.

Prostate cancer

- Prostate cancer is the most common form of cancer in men in the Western world.
- About 25% of those who have prostate cancer develop incurable castration-resistant prostate cancer (CRPC) with bone metastases.
- Today, there are only a handful of approved drugs that can prolong the lives of these patients. All of these drugs have more or less serious side effects. Each of these drugs currently has, or is expected to achieve, sales of over USD 1 billion annually, so-called blockbusters.

DexTech Medical

- After a limited time, CRPC becomes resistant to the respective drug, which means that the need for new complementary life-prolonging drugs is great.
- DexTech's lead candidate, OsteoDex, has the potential to become such a complementary drug.

The Phase IIb study

The original study protocol with ID ODX-002, was approved by the Swedish and Danish Medical Products Agencies in October 2014 (a placebo-controlled randomized multicenter phase II study) regarding OsteoDex for the treatment of castration-resistant prostate cancer with bone metastases (CRPC). On October 27, 2015, DexTech decided to change the study design and give all study patients active substance (OsteoDex). This is as a result of discussions with the Medical Products Agency in Uppsala and advice from "BigPharma". The study design was changed to active treatment for all patients. DexTech thus gains faster knowledge about the tumor-inhibiting effect in relation to dose, the efficacy parameter requested by prospective licensees. DexTech also responded to patients' requests for access to the active substance and thus avoid the risk of randomization to the placebo group. A decision to approve the new study protocol with ID ODX-003 was given by the Medical Products Agency in Uppsala on February 28, 2016.

The primary objective of the Phase II study was to document the efficacy of OsteoDex in the treatment of CRPC. The study included 55 well-defined CRPC patients. Patients were divided between three treatment arms (blinded distribution, 3 ascending dose levels of OsteoDex). The treatment was given for 5 months where OsteoDex was administered every two weeks. The study was conducted in Sweden (Norrländ University Hospital in Umeå, Södersjukhuset in Stockholm and University Hospital in Örebro), in Finland (Tampere University Hospital), in Estonia (East Tallin Central Hospital and Tartu University Hospital) and in Latvia (Riga East University Hospital and Daugavpils Regional Hospital). The first patient received his first treatment in September 2016 at Södersjukhuset in Stockholm.

In connection with these changes, the company chose to change the study organization by recruiting Crown-CRO Oy as GCP manager (good clinical practice) for the OsteoDex study. Crown-CRO Oy specializes in oncology studies in the Nordic and Baltic countries. Crown-CRO Oy replaces the company's former partner SynteractHCR.

In June 2018, the last patients in DexTech's phase IIb study for OsteoDex were completed. The work was then focused on the completion of the formal study report.

At the beginning of October 2018, DexTech was able to present the first results from the completed phase IIb study for Osteodex. The results obtained meet the primary objective of the protocol.

The Clinical Study Report (CSR) shows that 51 percent of patients completed the treatment (5 months, dose every two weeks). Of these, 52% showed stable disease (improved/unchanged) regarding bone metastasis. 35% of patients who completed treatment had a reduced tumour burden in the bones. The majority of the patients who had a reduced tumour burden in the skeleton had been treated with and no longer responded to two or more of the currently available drugs (docetaxel, cabazitaxel, abiraterone, enzalutamide, radium-223 dichloride) prior to enrolment in the study. This finding is of great importance for the continued clinical development of OsteoDex as the current patient group represents a significant so-called "unmet medical need". The results show that OsteoDex has a significant inhibitory effect on the vicious cycle ("vicious circle") in the skeleton, i.e. the biological process that drives this disease and thus also to shortened survival. More than 50% of patients showed marked decreases in the levels of markers related to bone metabolism and a particularly marked decrease was noted in 67% of patients for the marker CTX, which reflects bone degradation. The effect on this marker and other markers related to bone metastasis reflects the biological effect of the OsteoDex molecule. Tolerability was remarkably good with only few side effects. No patients needed to discontinue treatment due to adverse events and no OsteoDex-related serious adverse events (SAEs) were noted. The three dose arms in the protocol show equivalent treatment effect. The interpretation is that even the lower doses are sufficient to saturate the metastasis areas in the bones.

DexTech has previously reported promising follow-up results from the company's Phase IIb study of OsteoDex for the treatment of castration-resistant metastatic prostate cancer (mCRPC). Patients were then followed for survival for 24 months after completion of OsteoDex treatment. The results as of October 14, 2020 showed the following: of the patients who had stable (unchanged) bone metastasis disease at the end of treatment, 58% were alive, of the patients who had discontinued or discontinued treatment with progressive disease (progressive disease progression) were alive, and of the patients who had objective regression of bone metastases (reduction of existing bone metastases) at the end of treatment, 86% were alive. The results indicate prolonged survival after OsteoDex treatment.

DexTech Medical

DexTech announced on June 12, 2020 that the randomized phase IIb study for the treatment of bone metastatic castration-resistant prostate cancer (mCRPC) was completed with the receipt of 2-year follow-up results from the last patients.

The study's primary endpoints regarding markers of bone metabolism had been well achieved. A clear majority of patients showed a reduction in their bone markers in blood from the given treatment with OsteoDex. The treatment was very well tolerated (few and mild side effects) and good disease-inhibiting effect was seen even in the lowest doses. Slowing and regression of the disease was also seen in patients whose disease progressed after treatment with several of the other available medications for castration-resistant prostate cancer.

The study's secondary endpoints include overall survival that was studied through 24 months of follow-up after completion of treatment. Of the patients who responded to treatment, with slowing or stabilisation of the disease, the median survival had not yet been achieved (> 27 months, thus a positive result), compared to 14 months for the other patients (significance, $p < 0.05$). The 2-year survival rate after study entry was 65% for patients who responded to treatment, with disease slowing or stabilisation, compared to 28% for other patients (significance, $p < 0.05$).

The results of the study were very positive and show that OsteoDex effectively slows down the tumor disease. Data regarding overall survival should be seen as an indication, as these data, for natural reasons, need to be confirmed in a significantly larger, so-called Phase-III study.

None of the modern drugs are curative for castration-resistant prostate cancer and there is therefore a great need (unmet need) for new potent and tolerable drugs. OsteoDex has a clear potential to fill this need.

The continued clinical development of OsteoDex will be carried out by or together with a prospective licensee.

Preclinical research

OsteoDex has a mechanism of action against cancer cells that is general, and therefore other cancers have also been investigated as possible indications in addition to mCRPC, i.e. breast cancer, lung cancer and multiple myeloma.

Breast cancer

There are significant similarities between castration-resistant prostate cancer and advanced breast cancer in terms of propensity to metastasize to the bones. DexTech's preclinical studies conducted so far have clearly shown that OsteoDex has promising potential for the treatment of this form of cancer as well. The value of the breast cancer drug market (total sales) in the United States, Western Europe and Japan is estimated to be more than USD 15 billion by 2022 (Decision Resources 2013). The expanded preclinical program is part of the company's strategy to demonstrate OsteoDex's potential beyond the indication of castration-resistant prostate cancer.

Lung cancer

DexTech has previously announced data from preclinical studies regarding the effect of OsteoDex on the most common form of lung cancer, so-called non-small cell lung cancer (NSCLC). In conducted in vitro trials at Karolinska Institutet, OsteoDex shows a robust cell-killing effect in non-small cell lung cancer (NSCLC). The cell-killing effect was found to be completely on par with that seen in castration-resistant prostate cancer and breast cancer.

Lung cancer is divided into two main groups; non-small cell lung cancer and small cell lung cancer. Approximately 80 percent of all lung cancer cases are non-small cell lung cancer (NSCLC), which in turn is divided into several subgroups. Globally, >1.5 million people are diagnosed with lung cancer every year, and the vast majority of these die from it. The lack of active and well-tolerated drugs is strikingly great.

Multiple Myeloma

DexTech has conducted an extensive preclinical program regarding the effect of OsteoDex on multiple myeloma. In vitro experiments conducted at Karolinska Institutet show that OsteoDex has a robust cell-killing effect on myeloma cells. The cell-killing effect has been shown to be superior to the standard drug Melphalan.

DexTech Medical

MM is a form of blood cancer that starts in the bone marrow and causes the breakdown of the bones. The disease is incurable and the treatments that are currently available are used to, as far as possible, slow down the progression. The treatments often have severe side effects.

The company sees OsteoDex as very promising for the treatment of MM and has therefore decided to conduct a phase 1 study regarding the effect of OsteoDex on patients with multiple myeloma. This is based on OsteoDex's dual mechanism of action, inhibition of bone-degrading cells and tumor cell toxicity as well as with mild side effects, verified in clinical results.

On August 10, 2022, the Swedish Medical Products Agency approved and granted permission to conduct the phase 1 study regarding the effect of OsteoDex on patients with multiple myeloma.

DexTech announced on March 27, 2023 that the Company's Phase 1 study regarding the effect of OsteoDex on patients with multiple myeloma (MM) has been initiated and recruitment of patients has begun. The study includes 20 patients and is initially being conducted at three hospitals in Sweden: Karolinska University Hospital Huddinge, Uddevalla Hospital and Södersjukhuset in Stockholm. Another center in Sweden may be connected at a later date.

The study is expected to be completed in Q2, 2025. The Principal Investigator (PI) is Dr Katarina Uttervall, MD, PhD, Department of Hematology/HERM, Karolinska University Hospital Huddinge. Analysis of main blood markers takes place at the Central Laboratory, Karolinska University Hospital Solna, NKS. In accordance with the treatment schedule, OsteoDex is given every two weeks. The inclusion criteria include adult MM patients with *relapsed/treatment-resistant disease*, who received 1–5 prior lines of therapy. The primary objective is to confirm safety and tolerability. The secondary objective is to determine treatment response, change in the level of disease-related biomarkers, and documentation of quality of life.

PSMA-binding association

In June 2016, DexTech filed a patent application for important innovation regarding companion diagnostics and target-specific treatment of prostate cancer.

It is well known that prostate cancer cells on their surface overexpress (present in larger quantities) the protein PSMA (prostate-specific membrane antigen, i.e. PSMA is found in greater quantities on the surface of the tumor cell). Extensive international research activity is underway to produce molecules that can bind specifically to PSMA and thus be used as carriers of cancer cell-killing substances (radioactive isotopes, cytostatics, etc.) for so-called target-specific treatment of prostate cancer. Such molecules (including antibodies to PSMA) have been produced in several laboratories, but there are still challenges regarding production for clinical use, shelf life, patent protection, regulatory requirements, etc.

DexTech has developed a new PSMA-binding compound with the help of the company's technology platform. The new substance has unique properties in that it has multiple PSMA-binding parts and can carry a larger load of cell-killing substances than has been possible with PSMA-specific molecules produced so far. The production of the new substance can be relatively easily adapted to the company's GMP platform (i.e. manufacturing that is approved for clinical use). The current patent application complements and strengthens the company's other patents. DexTech intends to seek a development partner for the pre-clinical/clinical development of the new drug candidate.

In June 2016, DexTech filed a patent application for an important innovation (patent family 4) regarding diagnosis (so-called companion diagnostics) and target-specific treatment of prostate cancer, PSMA. This application was approved for a patent in Finland in June 2018. In the autumn of 2017, DexTech filed an international patent application (so-called PCT application). Patents have now been granted in Europe, Israel, Canada and Japan.

Patent

DexTech's patent portfolio includes four patent families and a new application for GMP manufacturing of OsteoDex (October 2023). Patents/applications provide strong protection of the Company's drug candidates and the Company's technology platform. The portfolio has a relevant geographical spread for DexTech. The Company's four patent families/patent applications are strongly related and each patent family is therefore relevant for all of the Company's drug candidates as well as for the platform, GuaDex. Patent applications are filed in countries where there is advanced pharmaceutical research and development and in countries that are larger markets for pharmaceutical products.

DexTech Medical

Patent family 1 - filed in 1999

Patent family 1 describes how the positively charged substance, CatDex, is selectively enriched in the tumor tissue, i.e. selectively relative to normal tissue.

Patent family 1 includes approved patents in Australia, Canada, the United States, and Europe (registered in Belgium, Switzerland, Germany, France, the United Kingdom, Italy, and Sweden). The patent was valid until October 12, 2019.

Patent family 2 filed in 2008

Patent family 2, the GuaDex patent, a further development of patent family 1, describes its tumor cell-killing properties against a number of different tumors, tumor cell cultures.

Patent family 2 includes approved patents in China, Finland, Israel, the United States, Mexico, Canada, Japan, and Europe (registered in Switzerland, Germany, France, the United Kingdom, Italy, and Sweden). The patent is valid until March 6, 2028.

Patent family 3 - filed in 2008

Patent family 3, the OsteoDex patent, is a GuaDex molecule with an additional component, a bisphosphonate, which has selectivity for the skeleton, i.e. where the metastasis is located.

Patent family 3 includes approved patents in China, Japan, Canada, Israel, Mexico, Brazil and Europe (registered in Switzerland, Germany, France, United Kingdom, Italy and Sweden). The patents are valid until April 7, 2028.

Patent family 4 - filed in 2016

In June 2016, DexTech filed a patent application for an important innovation (patent family 4) regarding diagnosis (so-called companion diagnostics) and target-specific treatment of prostate cancer, PSMA. This application was approved for a patent in Finland in June 2018. In the autumn of 2017, DexTech filed an international patent application (so-called PCT application). The application has been approved and patents have been granted in Europe, Israel, Canada and Japan. The patents are valid until 2036.

Patent family 5 - filed in 2023

The company has filed a new patent application with the European Patent Office regarding GMP manufacturing of OsteoDex (GMP= good manufacturing practice). Granted application means patent protection until about 2044. Access to GMP manufacturing is a prerequisite for conducting clinical research.

Prospects

DexTech's lead drug candidate OsteoDex has a unique dual mode of action, tumor-specific denaturation and inhibition of bone resorbing cells (osteoclasts). OsteoDex has been studied in a clinical phase II study with good results. There are significant similarities between bone metastases from mCRPC and Multiple Myeloma, such as growth site, bone degradation, and stimulation from osteoclasts.

These similarities have motivated DexTech's studies of OsteoDex's effects on Multiple Myeloma. In extensive preclinical studies conducted at Karolinska Institutet in Stockholm, the company has shown that OsteoDex has a very pronounced tumor cell-killing effect, which has been demonstrated on various Multiple Myeloma cell lines. OsteoDex shows strong efficacy even at low concentrations. Even compared to Melphalan, which is a proven standard drug for the treatment of multiple myeloma (MM), OsteoDex's effect is strikingly strong

The project is now being developed into clinical research and a formal protocol is being prepared. On August 10, 2022, the Swedish Medical Products Agency approved and granted the application for a phase 1 study regarding the effect of OsteoDex on patients with multiple myeloma. The study will include 20 patients and will be conducted at 3 hospital centers in Sweden. The study is expected to be completed in Q2 2025.

The intention is that the study will provide proof of concept and thus further verify OsteoDex's value as a potential cancer drug. The market for the new indication is estimated to be twice as large as that for mCRPC. The Rights Issue 2021 finances the Multiple Myeloma study and ensures continued operation until the end of 2025.

The continued clinical development of OsteoDex with the indication mCRPC, i.e. towards phase III, is very resource-intensive and requires large investments and will be carried out by a prospective larger partner. One of the motives/requirements for such an investment is patent protection, i.e. long market

DexTech Medical

exclusivity. With the new synthesis patent application approved, the requirement for long-term market exclusivity is met.

Organization

Anders R Holmberg is the CEO. The Board of Directors consists of Chairman of the Board Andreas Segerros and Board members Per-Olov Asplund, Peter Benson, Rolf Eriksson, and Svante Wadman.

Share

The DexTech share was listed on the Spotlight Stock Market on June 19, 2014. Trading is done under the designation DEX.


The number of outstanding shares at the beginning and end of the financial year amounted to 18,485,857.

Implemented incentive program

At the Annual General Meeting of DexTech AB on October 28, 2022, it was resolved to implement an incentive program ("TO 2022/2025") for pre-selected key employees ("Option Holders") that gave the Option Holders the opportunity to subscribe for warrants in DexTech for the market value in a directed share issue. The Board of Directors of DexTech resolved on the allocation of TO 2022/2025. The subscription price for the warrants in the directed issue was set in accordance with the terms and conditions at SEK 0.13 per warrant. Warrant holders are entitled, during the period from and including 25 November 2025 up to and including 9 December 2025, or the earlier date that follows from the complete terms and conditions, to request subscription of one (1) new share in the company for each warrant at a subscription price of SEK 25. Amounts in excess of the quota value shall be added to the unrestricted share premium reserve. As a result of TO 2022/2025, the number of shares at full exercise will increase by 200,000 shares. This corresponds to, based on the Company's current share capital, a dilution of a maximum of approximately one percent of the shares and votes. The increase in the Company's share capital may, upon full exercise of the warrants, amount to a maximum of SEK 9,000. Reservations are made for such recalculations as a result of issues, etc., that may be made in accordance with the terms and conditions of the warrants.

At the end of the financial year, the share price for DexTech Medical was SEK 4.24 and the reported equity per share was SEK 1.60. The market value amounted to SEK 78.4 million. The number of shareholders was 1,147.

Development of share price per share during the financial year 2023/2024



Related party transactions

Apart from board fees to the board members Andreas Segerros and Peter Benson as well as remuneration to the CEO and CFO, there are no related party transactions to report.

DexTech Medical

Accounting principles

This report has been prepared in accordance with the Annual Accounts Act and BFNAR 2012: 1 Annual Report and Consolidated Accounts (K3). The accounting principles are unchanged compared to the latest annual report.

Financial information

Annual report*	September 20, 2024
Q1 report 2024/2025	24 October 2024
AGM**	31 October 2024
Half-year report 2024/2025	February 27, 2025
Q3 report 2024/2025	April 29, 2025
Year-end report 2024/2025	August 30, 2025

* The annual report will be available on the Company's website www.dextechmedical.com September 20, 2024.

** The Annual General Meeting will be held in Stockholm on October 31, 2024.

Contact

Anders Holmberg, CEO, +46 73 324 27 82
Gösta Lundgren, CFO, +46 70 710 47 88

This information is such information that DexTech Medical AB is required to disclose in accordance with the EU Market Abuse Regulation. The information was submitted for publication on August 30, 2024 through the care of the above contact persons.

Stockholm August 30, 2024

DexTech Medical AB

Board of Directors

This report has not been reviewed by the Company's auditor.

This report is an in-house translation of the original report in Swedish

DexTech Medical AB
Dag Hammarskjölds Väg 34A, Uppsala
Mailing address:
Box 389, 752 23 Uppsala
www.dextechmedical.com

SUMMARY OF INCOME STATEMENTS

KSEK	Fourth Quarter		Full year	
	2024-04-01	2023-04-01	2023-07-01	2022-07-01
	2024-06-30	2023-06-30	2024-06-30	2023-06-30
Net sales	-	-	-	-
Work performed by the company for its own use and capitalized	1 605	1 655	5 385	8 711
Operating expenses	-3 212	-2 939	-10 934	-13 650
Operating profit/loss	-1 607	-1 284	-5 549	-4 939
Net financial profit/loss	315	171	843	349
Profit/loss before tax	-1 292	-1 113	-4 706	-4 590
Tax	-	-	-	-
Net profit/loss	-1 292	-1 113	-4 706	-4 590
Earnings per share, SEK *	-0,07	-0,06	-0,25	-0,25
Average number of shares, thousand *	18 485 857	18 485 857	18 485 857	18 485 857

* Before and after dilution.

SUMMARY BALANCE SHEETS

KSEK	2024-06-30	2023-06-30
Assets		
Intangible assets	10 907	9 211
Financial assets	1	1
Receivables	637	583
Cash and cash equivalents	19 043	25 236
Total assets	30 588	35 031
Equity and liabilities		
Equity	29 608	34 313
Current liabilities	980	718
Total equity and liabilities	30 588	35 031

SUMMARY CASH FLOW ANALYSIS

KSEK	2023-07-01	2022-07-01
	2024-06-30	2023-06-30
Cash flow from operating activities	-808	-1 552
Cash flow from investing activities	-5 385	-8 711
Cash flow from financing activities	-	26
Cash flow for the period	-6 193	-10 237
Cash and cash equivalents at the beginning of the period	25 236	35 473
Cash and cash equivalents at the end of the period	19 043	25 236